Saltar al contenido principal
QuantanSite

NVRA

NASDAQ

Novara Biotech

Healthcare · Biotechnology

Updated UTC

410,77 US$

+5,46+1,35 %

After hours412,82 US$+0,50 %

350,00400,0005/2106/2608/0309/0710/1311/18410,77

130 candlesRange +20,09 %

Key statistics

Open
405,06 US$
High
411,55 US$
Low
402,66 US$
Previous close
405,31 US$
Volumen
3,81 M
Average volume
3,14 M
Capitalización
393,65 mil M
P/E ratio
37,55
EPS
10,94 US$
Dividend yield
—
52-week high
412,94 US$
52-week low
295,67 US$

Financial statements

Units: USD · Annual
ItemFY2022FY2023FY2024FY2025FY2026
Revenue31,67 mil M37,26 mil M41,96 mil M48,31 mil M53,67 mil M
Gross profit18,76 mil M21,53 mil M23,9 mil M26,46 mil M32,34 mil M
Operating income6256,39 M7619,98 M7845,39 M9580,62 M11,72 mil M
Net income4883,1 M5629,58 M6171,13 M5775,42 M7645,85 M

About the company

Clinical-stage developer of oral therapies for autoimmune and metabolic disorders.

Related news

Demo
  • Novara Biotech reports quarterly revenue above the internal plan

    Novara Biotech said demand in its Biotechnology segment held up through the quarter, with management reiterating full-year margin guidance.

    Sector Desk

  • Novara Biotech expands manufacturing capacity in Cambridge

    The company approved a multi-year capital program intended to shorten lead times for its largest customers.

    Sector Desk

  • Analyst note trims Novara Biotech price target on valuation

    A sell-side desk kept a neutral rating while noting that near-term estimates already reflect steady execution.

    Sector Desk

  • Novara Biotech appoints new chief financial officer

    The board named an internal candidate with prior treasury and investor-relations experience to the role.

    Sector Desk

  • Novara Biotech announces share repurchase authorization

    The authorization covers a modest slice of the float and will be funded from operating cash flow.

    Terminal Brief